Regulation of the synthesis of plasminogen activator inhibitor type 1 (PAI-1): Pathogenetic mechanism of atherosclerosis in diabetes mellitus?

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 2, 1997, Pages 141-147

  Nordt, T K ^a,b   Peter, K ^a   Kubler W ^a   Bode, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETES MELLITUS; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; INSULIN METABOLISM; LIVER CELL; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0030726141     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80088-4     Document Type: Conference Paper

References (75)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
2. Falk E, Shah P K, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
3. Zhang Y, Cliff W J, Schoefl GI, Higgins G. Plasma protein insudation as an index of early coronary atherogenesis. Am J Pathol 1993; 143: 496-506.
4. Johnson-Tidey R R, McGregor J L, Taylor P R, Poston R N. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Am J Pathol 1994; 144: 952-961.
5. Davies MJ, Gordon J L, Gearing A J H, Pigott R, Woolf N. Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-229.
6. Faruqi R M, DiCorleto P E. Mechanisms of monocyte recruitment and accumulation. Br Heart J 1993; 69 (Suppl): S19-S29.
7. Hansson G K. Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 1993; 69(suppl): S38-S41.
8. Ylä-Herttuala S, Lipton B A, Rosenfeld M E, Särkioja T, Yoshimura T, Leonard E J, Witztum J L, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252-5256.
9. Rekhter M D, Gordon D. Does platelet-derived growth factor-A chain stimulate proliferation of arterial mesenchymal cells in human atherosclerotic plaques? Circ Res 1994; 75: 410-417.
10. Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
11. Ylä-Herttuala S, Rosenfeld M E, Parthasarathy S, Sigal E, Särkioja T, Witztum J L, Steinberg D. Gene expression in macrophage-rich human atherosclerotic lesions: 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest 1991; 87: 1146-1152.
12. Witztum J L. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
13. Demer L L, Watson K E, Boström K. Mechanism of calcification in atherosclerosis. Trends Cardiovasc Med 1994; 4: 45-49.
14. Berliner J A, Navab M, Fogelman A M, Frank J S, Demer L L, Edwards P A, Watson A D, Lusis A J. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
15. Bini A, Fenoglio J J, Mesa-Tejada R, Kudryk B, Kaplan K L. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989; 9: 109-121.
16. Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, Kuzuya F. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis 1992; 96: 227-234.
17. Smith E B, Cochran S. Factors influencing the accumulation of fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis 1990; 84: 173-181.
18. Davies M J. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996; 82: 1-32.
19. Andreotti F, Davies G J, Hackett D R, Khan M I, de Bart A C W, Aber V R, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635-637.
20. Angleton P, Chandler W L, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-106.
21. 1. Krishnamurti C, Barr C F, Hassett M A, Young G D, Alving B M. Plasminogen activator inhibitor: A regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803.
22. Vaughan D E, Declerck P J, van Houtte E, de Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68: 60-63.
23. Levi M, Biemond BJ, van Zonneveld A J, Wouterten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-! activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312.
24. Erickson L A, Fici G J, Lund J E, Boyle T P, Polites H G, Marotti K R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibit or-1 gene. Nature 1990; 346: 74-76.
25. Carmeliet P, Stassen J M, Schoonjans L, Ream B, van den Oord J J, de Mol M, Mulligan R C, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
26. Reilly C F, Fujita T, Hutzelmann J E, Mayer E J, Shebuski R J. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism. Circulation 1991; 84: 287-292.
27. Aznar J, Estellés A, Tormo G, Sapena P, Torino V, Blanch S, España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-541.
28. Olofsson B O, Dahlén G, Nilsson T K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
29. Huber K, Jörg M, Probst P, Schuster E, Lang I, Kaindl F, Binder B R. A decrease in plasminogen activator-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67: 209-213.
30. Verheugt F W A, ten Cate J W, Sturk A, Imandt L, Verhorst P M J, van Eenige M J, Verwey W, Ross J P. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 1987; 59: 1075-1079.
31. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
32. Hamsten A, de Faire U, Waldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; II: 3-8.
33. Salomaa V, Stinson V, Kark J D, Folsom A R, Davies C E, Wu K K. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Circulation 1995; 91: 284-290.
34. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati M B, Cardillo M, Catalane M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. Arterioscler Thromb 1993; 13: 1412-1417.
35. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Haemost 1990; 16; 207-216.
36. Grimaudo V, Bachmann F, Hauert J, Christa M A, Kruithof EKO. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Thromb Haemost 1992; 67: 397-401.
37. Barbash G I, Hod H, Roth A, Miller H I, Rath S, Har Zahav Y, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-1235.
38. Sane D C, Stump D C, Topol E J, Sigmon K N, Kereiakes D J, George B S, Mantell S J, Macy E, Collen D, Califf R M. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991; 65: 275-279.
39. Schleef R R, Higgins D L, Pillemer E, Levitt L J. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-1752.
40. Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-532.
41. Fay W P, Shapiro A D, Shih J L, Schleef R R, Ginsburg D. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-1733.
42. Lee M H, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-2362.
43. Factor S M, Segal B H, van Hoeven K H. Diabetes and coronary artery disease. Coronary Artery Disease 1992; 3: 4-10.
44. Califf R M, Fortin D F, Frid D J, Harlan III W R, Ohman E M, Bengtson J R, Nelson C L, Tcheng J E, Mark D B, Stack R S. Restenosis after coronary angioplasty: An overview. J Am Coll Cardiol 1991; 17: 2B-13B.
45. Sobel B E. Potentiation of vasculopathy by insulin: Implications from an NHLBI Clinical Alert. Circulation 1996; 93: 1613-1615.
46. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-225.
47. Juhan-Vague I, Alessi M C, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
48. Schneider D J, Nordt T K, Sobel B E. Attenuated fibrinolysis and accelerated atherosclerosis in type II diabetic patients. Diabetes 1993; 42: 1-7.
49. Kooistra T. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis. Fibrinolysis 1990; 4 (Suppl 2): 33-39.
50. Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezati L, Lorenzi M. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992; 41: 1009-1015.
51. Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M. Expression of genes related to the extracellular matrix in human endothelial cells. J Biol Chem 1991; 266: 14244-14250.
52. Nordt T K, Klassen K J, Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-1828.
53. Hughes H H. Swine in cardiovascular research. Lab Anim Sci 1986; 36: 348-350.
54. van Hinsbergh V W M, Binnema D, Scheffer M A, Sprengers E D, Kooistra T, Rijken D C. Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis 1987; 7: 389-400.
55. Nordt T K, Schneider D J, Sobel B E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 (PAI-1) by precursors of insulin: A potential risk factor for vascular disease. Circulation 1994; 89: 321-330.
56. Sobey W J, Beer S F, Carrington C A, Clark P M S, Frank B H, Gray I P, Luzio S D, Owens D R, Schneider A E, Siddle K, Temple R C, Hales C N. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 1989; 260: 535-541.
57. Bowsher R R, Wolny J D, Frank B H. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum. Diabetes 1992; 41: 1084-1090.
58. Temple R C, Clark P M S, Nagi D K, Schneider A E, Yudkin J S, Haies C N. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol 1990; 32: 689-693.
59. Nagi D K, Hendra T J, Ryle A J, Cooper T M, Temple R C, Clark P M S, Schneider A E, Hales C N, Yudkin J S. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
60. Heding L G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8; 260-266.
61. Alessi MC, Juhan-Vague I, Kooistra T, Declerck P J, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-494.
62. Kooistra T, Bosma P J, Tons HAM, van den Berg A P, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 123-128.
63. Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88: 9959-9963.
64. Spradlin C T, Galloway J A, Anderson J H. Apparent increase in coronary heart disease with human proinsulin (HPI) -Randomization failure or HPI effect? Diabetologia 1990; 33(suppl): A60.
65. Galloway J A, Hooper S A, Spradlin C T, Howey D C, Frank B H, Bowsher R R, Anderson J H. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992; 15: 666-692.
66. Jain S K, Nagi D K, Slavin B M, Lumb P J, Yudkin J S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycemic control. Diabetic Med 1993; 10: 27-32.
67. Misbin RI, Merimee T J, Lowenstein J M. Insulin removal by isolated perfused rat liver. Am J Physiol 1976; 230: 171-177.
68. Glauber H S, Henry R R, Wallace P, Frank B H, Galloway J A, Cohen R M, Olefsky J M. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1987; 316: 443-449.
69. Nordt T K, Sawa H, Fujii S, Sobel B E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770.
70. Fujii S, Sobel B E. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 1990; 82: 1485-1493.
71. Nordt T K, Sawa H, Fujii S, Sobel B E. Hyperinsulinemia increases plasma activity of PAI-1 in vivo independently of an acute phase reaction. Fibrinolysis 1997; 11: (in press).
72. Grant P J, Kruithof E K O, Felley C P, Felber J P, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-516.
73. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 1991; 65: 130-133.
74. Vuorinen-Markkola H, Puhakainen I, Yki-Järvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 1992; 67: 117-120.
75. Potter van Loon BJ, de Bart ACW, Radder JK, Frölich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 4 (Suppl 2): 93-94.